Biora Therapeutics, Inc. (BIOR)
NASDAQ: BIOR · Real-Time Price · USD
1.610
-0.010 (-0.62%)
Nov 21, 2024, 1:49 PM EST - Market open

Company Description

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States.

The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.

The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.

Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Biora Therapeutics, Inc.
Biora Therapeutics logo
Country United States
Founded 2010
IPO Date Jun 19, 2020
Industry Biotechnology
Sector Healthcare
Employees 58
CEO Aditya Mohanty

Contact Details

Address:
4330 La Jolla Village Drive, Suite 300
San Diego, California 92122
United States
Phone 833 727 2841
Website bioratherapeutics.com

Stock Details

Ticker Symbol BIOR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001580063
CUSIP Number 74319F107
ISIN Number US74319F3055
Employer ID 27-3950390
SIC Code 2834

Key Executives

Name Position
Aditya P. Mohanty M.B.A. Chief Executive Officer and Director
Eric d'Esparbes Chief Financial Officer
Clarke Neumann J.D. Senior Vice President, General Counsel and Secretary
Robyn Hatton Head of Human Resources
Kevin Howe Ph.D. Senior Vice President of Strategic Operations
Dr. Sharat Singh Ph.D. Head of Research
Dr. Paul Shabram M.B.A. Head of Technical Operations
Ariella Kelman M.D. Chief Medical Officer
James Knight M.B.A. Head of Business Development

Latest SEC Filings

Date Type Title
Nov 15, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 8-K Current Report
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 29, 2024 8-K Current Report
Oct 29, 2024 424B5 Filing
Oct 29, 2024 424B3 Prospectus
Oct 29, 2024 424B3 Prospectus
Oct 29, 2024 424B3 Prospectus
Oct 29, 2024 424B3 Prospectus